KROS Q1 2020 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KROSKeros Therapeutics, Inc.

$424M

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$11M

Net Income

-$12M

EPS (Diluted)

$-0.70

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$12,000

Balance Sheet

Total Assets

$61M

Total Liabilities

$85M

Stockholders' Equity

-$25M

Cash & Equivalents

$55M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$3M	-100.0%
Gross Profit	$0	$0	—
Operating Income	-$11M	-$3M	-267.5%
Net Income	-$12M	-$3M	-273.6%